RARA and acute promyelocytic leukemia: Furthermore, the combination of RA with HDAC inhibitors in patients with RA-resistant APL (such as those bearing the PLZF–RAR chimera) has produced encouraging clinical responses, although some blasts remain resistant to differentiation [88,90].